This Web site may contain links or references to other Web sites maintained by third parties over whom Teva, Inc. ("Teva") has no control. Links are provided as a convenient resource to our visitors. We carefully choose Web sites which we believe are useful based on our high standards. However, Web sites can change. Teva cannot guarantee the standards of every Web site link or be responsible for the content of non-Teva Web sites. Inclusion of any third-party link does not imply an endorsement or recommendation by Teva.
Similarly, this Web site may be accessed from third-party links over which Teva has no control. Teva makes no warranties or representations of any kind as to the accuracy, currency, or completeness of any information contained in such Web sites and shall have no liability for any damages or injuries of any kind arising from such content or information.
patients received AJOVY as a stand-alone preventive treatment1
patients continued to receive their oral preventive treatment1
Nearly 600 patients had discontinued prior preventive treatment2
of women of childbearing age also took concomitant hormonal contraceptives2
There are no adequate data on the developmental risk associated with the use of AJOVY in pregnant women. This should be taken into consideration for women who are pregnant or plan to become pregnant while using AJOVY.1
AJOVY Quarterly (n=376) | AJOVY Monthly (n=379) | Placebo (n=375) | |
---|---|---|---|
Age (y), mean (SD) | 42.0 (12.4) | 40.6 (12) | 41.4 (12) |
Female, n (%) | 331 (88) | 330 (87) | 330 (88) |
Concomitant preventive medication use, n (%) | 77 (20) | 85 (22) | 77 (21) |
Concomitant acute headache medication use, n (%) | 359 (95) | 360 (95) | 358 (95) |
Discontinued prior preventive treatment, n (%) | 130 (35) | 141 (37) | 136 (36) |
AJOVY Quarterly (n=291) | AJOVY Monthly (n=290) | Placebo (n=294) | |
---|---|---|---|
Age (y), mean (SD) | 41.1 (11.4) | 42.9 (12.7) | 41.3 (12) |
Female, n (%) | 251 (86) | 244 (84) | 247 (84) |
Concomitant preventive medication use, n (%) | 58 (20) | 62 (21) | 62 (21) |
Concomitant acute headache medication use, n (%) | 281 (97) | 279 (96) | 280 (95) |
Discontinued prior preventive treatment, n (%) | 58 (20) | 65 (22) | 63 (21) |